OrthoPediatrics delivered a strong fourth quarter with revenue growing 17% year-over-year to $61.6 million, driven by robust performance in the Scoliosis and Trauma & Deformity segments. While the company reported a net loss of $10.1 million, it achieved positive Adjusted EBITDA of $4.8 million for the quarter and provided a positive outlook for 2026, targeting free cash flow breakeven.

OrthoPediatrics delivered a strong third quarter in 2025, achieving record high total revenue of $61.2 million, a 12% increase year-over-year. The company also significantly improved its adjusted EBITDA by 56% to $6.2 million and reduced free cash flow usage by $8.2 million. Despite a GAAP diluted loss per share of $(0.50), the company saw robust growth in its Trauma & Deformity and Scoliosis segments, driven by strategic initiatives and new product approvals.

OrthoPediatrics delivered a strong second quarter in 2025, achieving record-high total revenue of $61.1 million, a 16% increase year-over-year, driven by robust growth in Scoliosis and Trauma & Deformity segments. The company also significantly improved its Adjusted EBITDA by 58% to $4.1 million and reduced its non-GAAP diluted loss per share. This performance led to an increase in full-year 2025 revenue guidance.

OrthoPediatrics delivered a strong first quarter 2025 performance, with total revenue increasing 17% year-over-year to $52.4 million. The company also improved its adjusted EBITDA and reduced free cash flow usage, while expanding its scoliosis portfolio with a new system launch.

OrthoPediatrics Corp. reported Q4 2024 revenue of $52.7 million, up 40% year-over-year, driven by strong growth in Trauma and Deformity, Scoliosis, and the addition of Boston O&P. Despite this, the company reported a net loss of $16.1 million, widening from $6.7 million in the prior year. Adjusted EBITDA improved to $3.0 million from $1.3 million. Gross margin declined slightly due to reclassified costs. The company reiterated its 2025 revenue guidance of $235 million to $242 million.

OrthoPediatrics Corp. announced strong third-quarter results with a 37% increase in revenue compared to the same period last year. The company also increased its full-year revenue guidance for 2024, reflecting positive momentum and strategic execution across all business segments.

OrthoPediatrics Corp. announced its Q2 2024 financial results, achieving record revenue of $52.8 million, a 33% increase compared to the same period last year. The company helped a record 32,000 children, marking a 52% increase from Q2 2023. They reaffirmed their full-year 2024 revenue guidance of $200.0 million to $203.0 million.

OrthoPediatrics Corp. reported a 41% increase in revenue for Q1 2024, reaching $44.7 million, driven by growth in Trauma & Deformity and Scoliosis products, as well as the acquisition of Boston O&P. The company increased its full-year revenue guidance to $200.0 million to $203.0 million.

OrthoPediatrics Corp. announced its Q4 and full year 2023 financial results, with Q4 revenue increasing by 21% to $37.6 million compared to the same period last year. The company's growth was primarily driven by Global Trauma and Deformity, Domestic Scoliosis, and OPSB. The net loss for the quarter was $6.7 million, an improvement compared to the $7.8 million loss in the same period last year. Adjusted EBITDA for the fourth quarter of 2023 was $1.3 million as compared to a loss of $2.2 million for the fourth quarter of 2022.

OrthoPediatrics Corp. reported record-setting quarterly revenue of $40.0 million for Q3 2023, a 14% increase compared to the same period last year. The company also achieved record Adjusted EBITDA of $3.6 million. They reiterated full year 2023 revenue guidance of $148.0 million to $151.0 million and raised adjusted EBITDA guidance to $4.0 million to $5.0 million for the full year of 2023.

OrthoPediatrics Corp. reported a strong second quarter in 2023, achieving record revenue of $39.6 million, a 20% increase compared to the same period last year. The company experienced growth across all revenue segments and geographies, driven by new product development, set consignments, and surgeon training.

OrthoPediatrics Corp. reported a strong first quarter in 2023 with a 35% increase in revenue compared to the same period last year. The company's U.S. and international revenues grew by 31% and 49%, respectively. The growth was primarily driven by organic growth in Trauma and Deformity and Scoliosis products as well as the addition of MD Ortho and Pega Medical. The company also increased its full-year revenue guidance for 2023.

OrthoPediatrics Corp. announced its Q4 2022 financial results, with revenue increasing by 25% year-over-year to $31.0 million. The company experienced growth in both domestic and international markets, driven by its core businesses and recent acquisitions. However, the company reported a net loss of $7.8 million for the quarter.

OrthoPediatrics Corp. reported a 39% increase in revenue for the third quarter of 2022, reaching $35.0 million compared to $25.1 million in the same period last year. This growth includes contributions from recent acquisitions MD Ortho and Pega Medical. The company's net income for the quarter was $18.5 million, a significant improvement from the net loss of $2.2 million in the third quarter of 2021.

OrthoPediatrics Corp. announced its Q2 2022 financial results, highlighted by a 23% increase in total revenue to $32.9 million and a record adjusted EBITDA of $2.1 million. The company also increased its full-year 2022 revenue guidance to a range of $127 million to $130 million.

OrthoPediatrics Corp. reported a 9% increase in revenue for Q1 2022, reaching $23.4 million compared to $21.5 million in Q1 2021. The company's U.S. revenue increased by 8%, while international revenue grew by 13%. Trauma and Deformity revenue increased by 13%, Scoliosis revenue increased by 1%, and Sports Medicine/Other revenue decreased by 4%. The company has increased its full year 2022 revenue guidance to $122 million to $125 million.

OrthoPediatrics Corp. reported a 31% increase in revenue for the fourth quarter of 2021, reaching $24.8 million compared to $18.9 million in the same period last year. The growth was primarily driven by strong performance in trauma and deformity, with international revenue showing a significant increase. The company also issued full year 2022 revenue guidance of $118 million to $121 million and expects positive adjusted EBITDA for the full year 2022.

OrthoPediatrics reported a 13% increase in revenue for Q3 2021, reaching $25.1 million compared to $22.2 million in Q3 2020. The company's international revenue saw a significant increase of 118%, while U.S. revenue declined by 1%. Despite challenges from COVID-19, RSV, and hospital staffing shortages, the company reiterated its full-year revenue guidance of $97-$101 million.

OrthoPediatrics reported a 96% increase in total revenue for Q2 2021, reaching $26.7 million, compared to $13.6 million in Q2 2020. The company saw robust growth in both U.S. and international markets, with U.S. revenue increasing by 79% and international revenue increasing by 243%.

OrthoPediatrics reported a strong first quarter with a 31.2% increase in revenue compared to the same period last year. The company saw growth in both domestic and international markets, as well as across all product categories. Gross profit margin improved, and the company is well-positioned for sustained growth.

OrthoPediatrics reported Q4 2020 revenue of $18.9 million, a 0.1% decrease compared to Q4 2019. The company experienced a $2.7 million revenue reduction due to a distributor conversion in Germany, Austria, and Switzerland. Domestic revenue grew by 26.1%, while international sales agency revenue increased by 51%.

OrthoPediatrics Corp. reported a 7.0% increase in total revenue for Q3 2020, reaching $22.2 million, driven by a 16.7% growth in U.S. revenue. The company also achieved positive adjusted EBITDA, reflecting strong gross margin and cost control.

OrthoPediatrics Corp. reported a 25.3% decrease in total revenue for Q2 2020, totaling $13.6 million, compared to $18.2 million in Q2 2019. The decline was primarily due to the impact of the COVID-19 pandemic. Despite the decrease, the company saw significant monthly improvement throughout the quarter and continued to execute key initiatives, including the acquisition and launch of the ApiFix system.

OrthoPediatrics Corp. announced its financial results for the first quarter ended March 31, 2020, reporting a total revenue of $16.4 million, up 11.6% from $14.7 million in the first quarter of 2019. The company saw strong domestic revenue growth of 30.4% and continued to advance its strategic initiatives, including the acquisition of ApiFix and the launch of new products.

OrthoPediatrics Corp. reported a strong fourth quarter and full year 2019, marked by a 30.1% increase in Q4 revenue to $19.0 million and a 26.0% increase in full-year revenue to $72.6 million. The company launched new products, expanded its sales organization, and strengthened its cash position through a follow-on offering.